The Trump administration, along with Robert F. Kennedy Jr., has announced a bold $500 million project aimed at developing a universal vaccine for influenza and COVID-19. This initiative, which relies on older vaccine technology, has raised eyebrows among scientists who express confusion over the decision, characterizing it as a puzzling bet on a less innovative approach. Concerns about favoritism and the scientific risks associated with the project have surfaced, leading to accusations of cronyism in the allocation of funds. As the National Institutes of Health begins this ambitious endeavor, many are left wondering about the potential implications for public health.